Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating

Congenital heart defects are the most common type of birth defect, affecting nearly 1% of all births, or about 40,000 babies in the United States each year. Although many heart defects can be treated with surgery, most people are not completely cured and require lifelong medical care.

Add as your preferred news

Source and reference

source on Google Add Now Congenital heart defects are the most common type of birth defect, affecting nearly 1% of all births, or about 40,000 babies in the United States each year. Although many heart defects can be treated with surgery, most people are not completely cured and require lifelong medical care. One of the most severe forms is Hypoplastic Left Heart Syndrome (HLHS), which accounts for 2-3% of all congenital heart defects. The company we are profiling today is Longeveron Inc. ( LGVN ) , which is developing a therapy for hypoplastic left heart syndrome (HLHS). Subscribe to continue reading the article. This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription. Start Free Trial FREE 7-Day Trial - No Payment Required Already subscribed? Sign in For comments and feedback contact...

Read original source

Why this matters locally

This business story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.

Local impact

BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.

Timeline